Business Context and Reporting Period
This Form 6-K filing is dated June 29, 2017, and is submitted by Prima BioMed Ltd, a foreign private issuer headquartered in Sydney, Australia. The filing serves to incorporate by reference a Registration Statement on Form F-3 (No. 333-211702). The document details a corporate financing event involving a Placement Agency Agreement with Maxim Group LLC, executed on the filing date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the execution of legal agreements related to a securities offering rather than reporting periodic financial performance results.
Material Changes
The primary material change disclosed is the execution of a Placement Agency Agreement and a Securities Purchase Agreement on June 29, 2017. These agreements facilitate the issuance of American Depositary Shares (ADS) and warrants to purchasers. No comparative financial data or operational changes versus prior periods are detailed in this specific filing.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and specific risk factors are not included in the text of this Form 6-K. The filing is a procedural disclosure of the transaction documents (Exhibits 99.1, 99.2, and 99.3) rather than an earnings release or strategic update. The filing notes that the report is incorporated by reference into the Form F-3 registration statement, which may contain further details on the offering.
Investor Verification Checklist
- Verify the total number of American Depositary Shares and warrants issued under the Securities Purchase Agreement.
- Confirm the purchase price per share and the total gross proceeds raised from the offering.
- Review the terms of the Placement Agency Agreement with Maxim Group LLC for commission fees and underwriting obligations.
- Examine the Form F-3 Registration Statement (No. 333-211702) for detailed use of proceeds and risk factors associated with the capital raise.